Andrew M. Stern, Ph.D.
|Ph.D. in Biological Chemistry, University of California at Los Angeles|
3501 Fifth Avenue
The overarching goal of our research is to identify mechanisms involved in complex human disease progression and use this knowledge to develop novel therapies for individual patients. We apply a holistic clinically relevant quantitative systems biology and pharmacology approach. This involves the development, implementation, and integration of several high throughput and high content molecular and cell-based technologies and models to comprehensively define fundamental biological processes that are perturbed in particular diseases.
Wang P, Bahreini A, Gyanchandani R, Lucas P, Hartmaier RJ, Watters RJ, Jonnalagadda AR, Trejo Bittar HE, Berg A, Hamilton RL, Kurland BF,Weiss K, Mathew A, Leone JP, Davidson NE, Nikiforova MN, Brufsky AM, Ambros TF, Stern AM, Puhalla S, Lee AW, Oesterreich S.(2015) Sensitive detection of mono- and polyclonal ESR1 mutations in primary tumors, metastatic lesions and cell free DNA of breast cancer patients Clin Cancer Res. [Epub ahead of print].
Boisen MM, Andersen CL, Sreekumar S, Stern AM, Oesterreich S (2015) Treating Gynecologic Malignancies with Selective Estrogen Receptor Downregulators (SERDs): Promise and Challenges Mol Cell Endocrinol. 418 Pt 3:322-33.
Chattopadhyay S, Stewart AL, Mukherjee S, Huang C, Hartwell KA, Miller PG, Subramanian R, Carmody LC, Yusuf RZ, Sykes DB, Paulk J, Vetere A, Vallet S, Santo L, Cirstea DD, Hideshima T, Dančík V, Majireck MM, Hussain MM, Singh S, Quiroz R, Iaconelli J, Karmacharya R, Tolliday NJ, Clemons PA, Moore MA, Stern AM, Shamji AF, Ebert BL, Golub TR, Raje NS, Scadden DT, Schreiber SL (2015) Niche-Based Screening in Multiple Myeloma Identifies a Kinesin-5 Inhibitor with Improved Selectivity over Hematopoietic Progenitors Cell Rep. 10(5): 755-70.